Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer's disease

Jeffrey Y. Huang, Daniel M. Hafez, Bryan D. James, David A. Bennett, Robert A. Marr

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Neprilysin-2 (NEP2), a close homolog of neprilysin (NEP), degrades amyloid-β (Aβ) and serves an important role in clearing Aβ in vivo. We measured NEP2 and NEP mRNA levels from non-impaired (NI), mild cognitive impaired (MCI), and clinical Alzheimer's disease (AD) subjects in the mid-temporal gyrus, mid-frontal gyrus, caudate, and cerebellum. NEP2 activity levels were also determined. Our results indicate that NEP2 and NEP mRNA expression is altered in MCI subjects relative to NI subjects in AD-susceptible regions. NEP2 enzymatic activity was lowered in association with MCI and AD and was positively associated with cognitive function, independent of diagnostic category. Our finding that NEP2 expression and activity are altered in MCI is significant as these changes may potentially serve as preclinical markers for AD and reduced NEP2 activity may be associated with the development of AD.

Original languageEnglish
Pages (from-to)433-441
Number of pages9
JournalJournal of Alzheimer's Disease
Issue number2
StatePublished - 2012


  • Alzheimer's disease
  • amyloid-β peptide
  • biomarker
  • human brain
  • neprilysin
  • neprilysin-2


Dive into the research topics of 'Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer's disease'. Together they form a unique fingerprint.

Cite this